Shandong Boan Biotechnology CoFRA:UJ9 39 Altman Z-Score is 1.65 as of Jul. 06, 2026, which is 50% below its 10-year median of 3.32. GuruFocus rates FRA:UJ9 with a GF Score™ of 39/100 and a GF Value™ of €1.70. The stock has 5 warning signs investors should review. Among 924 Biotechnology companies, Shandong Boan Biotechnology Co ranks worse than 58.01% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.62 is in distress zone. This implies bankruptcy possibility in the next two years.
Shandong Boan Biotechnology Co has a Altman Z-Score of 1.65, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Shandong Boan Biotechnology Co's Altman Z-Score or its related term are showing as below:
FRA:UJ9'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.62 Med: 3.32 Max: 6.55
Current: 1.62
During the past 6 years, Shandong Boan Biotechnology Co's highest Altman Z-Score was 6.55. The lowest was 1.62. And the median was 3.32.
Shandong Boan Biotechnology Co (FRA:UJ9) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co Altman Z-Score Chart
FRA:UJ9 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's Altman Z-Score falls into.
Shandong Boan Biotechnology Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Shandong Boan Biotechnology Co (FRA:UJ9) has a Altman Z-Score of 1.65 as of Jul. 06, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Shandong Boan Biotechnology Co and its competitors. This is 50% below median its historical median of 3.32. Over the past decade, Shandong Boan Biotechnology Co's Altman Z-Score has ranged from 1.62 to 6.55. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #536 out of 924 companies in the Biotechnology industry, placing it in the top 58%.
Is Shandong Boan Biotechnology Co's Altman Z-Score too high?
Shandong Boan Biotechnology Co's current Altman Z-Score of 1.65 is 50% below median its 10-year median of 3.32. Over the past 10 years, this metric has ranged from a low of 1.62 to a high of 6.55. The Biotechnology industry median Altman Z-Score is 2.77. Shandong Boan Biotechnology Co's value of 1.65 is 40.3% below this industry median. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #536 out of 924 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #536 out of 924 companies for Altman Z-Score. This places Shandong Boan Biotechnology Co in the lower half of its industry. The industry median Altman Z-Score is 2.77. Shandong Boan Biotechnology Co's value of 1.65 is 40.3% below this benchmark. Historically, Shandong Boan Biotechnology Co's own Altman Z-Score has ranged from 1.62 to 6.55 over the past decade. While the company's 10-year median is 3.32 vs. the industry median of 2.77, Shandong Boan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.77, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Boan Biotechnology Co's current Altman Z-Score of 1.65 is 40.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Shandong Boan Biotechnology Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current Altman Z-Score is 1.65, which is 50% below median its own 10-year median of 3.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Altman Z-Score of 1.65. The stock's GF Value™ is €1.70, compared to a current price of €0.56 — trading 67.1% below its estimated fair value. The current Altman Z-Score is 1.65, which is 50% below median its 10-year median of 3.32 and 40.3% below the Biotechnology industry median of 2.77. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Altman Z-Score is 1.65 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.56 is trading 67.1% below its estimated GF Value™ of €1.70.
Key valuation signals for FRA:UJ9:
Altman Z-Score: 1.65 (50% below median its 10-year median of 3.32)
GF Value™: €1.70 vs. price of €0.56 (67.1% below fair value)
Industry Position: 40.3% below the Biotechnology median (#536 of 924)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score
Get the complete analysis for FRA:UJ9
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
